Writing group disclosures

Writing group memberEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOther
Caroline S. FoxNHLBINoneNoneNoneNoneNoneNoneNone
Sherita Hill GoldenJohns Hopkins UniversityNIH†NoneNoneNoneNoneNoneNone
Cheryl AndersonUniversity of California at San DiegoNoneNoneNoneNoneNoneNoneNone
George A. BrayPennington Biomedical Research CenterNIHNoneTakeda*NoneNoneNovo-Nordisk*; Herbalife*; Medifast*NIH
Lora E. BurkeUniversity of PittsburghNIHNoneNoneNoneNoneNoneNHLBI
Ian H. de BoerUniversity of WashingtonAbbvie; Medtronic*NoneNoneNoneNoneBayer*; Amgen*None
Prakash DeedwaniaUCSF Fresno ProgramNoneNoneNoneNoneNoneNoneNone
Robert H. EckelUniversity of ColoradoJanssen†NoneNoneNoneNoneJanssen*; Regeneron; SanofiJanssen*
Abby G. ErshowNIH Office of Dietary SupplementsNoneNoneNoneNoneJohnson & JohnsonNoneNone
Judith FradkinNIH/NIDDKNoneNoneNoneNoneNoneNoneNIH/NIDDK
Silvio E. InzucchiYale University School of MedicineTakedaNoneNonePfizer*; Takeda*NoneBoehringer Ingelheim; AstraZeneca*; Merck*; Novo Nordisk*; Regeneron*; Janssen*None
Mikhail KosiborodMid America Heart InstituteGilead; Genentech; Sanofi Aventis; Eisai; AstraZenecaGileadNoneNoneNoneAstraZeneca; Eli Lilly*; Regeneron*; Roche*; Gilead*; Amgen†; Takeda*; Edwards Lifesciences*; Glytec*; GSK*; ZS PharmaNone
Robert G. NelsonNational Institutes of HealthNoneNoneNoneNoneNoneNoneNone
Mahesh J. PatelMerck Research LaboratoriesNoneNoneNoneNoneNoneNoneMerck Research Laboratories
Michael PignoneUniversity of North CarolinaNoneNoneNoneNoneNoneNoneNone
Laurie QuinnUniversity of Illinois at ChicagoNoneNoneNoneNoneNoneNoneNone
Philip R. SchauerCleveland ClinicSTAMPEDE Trial; ARMMS TrialNoneNoneNoneSE Quality Healthcare Consulting; SurgiQuest*Ethicon*; Nestle*; Intuitive*None
Elizabeth SelvinJohns Hopkins Bloomberg School of Public HealthNIH/NIDDKNoneNoneNoneNoneNoneNone
Dorothea K. VafiadisAmerican Heart AssociationNoneNoneNoneNoneNoneNoneNone
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.